Mindera

Mind.Px helps physicians confidently prescribe the right biologic drug class for psoriasis patients.

Patients treated with biologics guided by Mind.Px test results showed faster disease improvement than those without test results.

Mind.Px is a predictive test using a dermal biomarker patch to extract mRNA for transcriptomic analysis and machine learning-based results with >91% positive predictive value.

Psoriasis Predictive Test Training

Mindera Health In-Office Video Training

A survey of 43 dermatologists found 98% would use Mindera’s Mind.Px to predict biologic treatment response in psoriasis patients.

Vista, CA, March 18, 2026 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, and Mountaineer Biosciences today announced the launch of Subtilitas, a precision translational medicine platform designed to bring objective, molecular-level insights into dermatology and immunology clinical research Subtilitas integrates non-invasive skin sampling, advanced molecular profiling, and artificial intelligence/machine

A clinical trial showed Mind.Px test results altered physician prescribing behavior, leading to faster and more effective patient outcomes.

Mindera Health received approval from the New York State Department of Health for its Mind.Px genomic test in psoriasis.

Mindera Health and the Perelman School of Medicine collaborate to study quinacrine’s mechanism in treatment-resistant cutaneous lupus using the Dermal Biomarker Patch and Subtilitas Platform.

Mindera Health’s Mind.Px test predicts patient response to psoriasis biologic drugs, improving treatment management and reducing healthcare costs.

Andrew Offer has served on Mindera’s Board of Directors since 2015 and is CEO of Scientific Health Development.

Dr. Mark Lebwohl graduated summa cum laude from Columbia College in 1974 and from Harvard Medical School in 1978, completing residencies in internal medicine and dermatology at Mount Sinai.

Mindera Health offers Mind.Px to help psoriasis patients.

Mindera Health’s technology captures RNA transcripts from a penny-sized patch in five minutes for personalized genetic analysis.

Mindera Health partners with the University of Pennsylvania to study cutaneous lupus erythematosus treatments. The collaboration combines Mindera’s **Dermal Biomarker Patch™** and **Subtilitas Platform** with Penn’s immunology research to investigate the potential of **quinacrine** in managing the condition. The project aims to leverage translational science for therapeutic insights.

Sep 2026GlobeNewswireNews article

Mindera Health secures New York State Department of Health approval for its **Mind.Px** genomic test, expanding its precision medicine offering for psoriasis to all 50 states. The test leverages proprietary technology to deliver targeted diagnostics for dermatological conditions. This approval follows Mindera Health’s established position as a leader in precision dermatology solutions.

Apr 2026Mindera Health - Shaping the Era of Digital Predictive Skin AnalyticsNews article

Mindera Health and Mountaineer Biosciences introduce **Subtilitas**, a precision medicine platform combining non-invasive skin sampling, molecular profiling, and AI-driven analysis. The platform captures disease-specific biological signals from skin to improve dermatology and immunology research beyond traditional visual assessments and invasive biopsies.

Mar 2026Yahoo FinanceNews article

Mindera Health publishes a randomized, prospective clinical utility study showing its **Mind.Px™** test influences physician prescribing behavior. The study links these changes to **faster and more effective outcomes for psoriasis patients**, based on altered treatment approaches guided by test results. The findings highlight the test’s potential to optimize psoriasis management through data-driven prescribing decisions.

May 2025GlobeNewswireNews article